Results 181 to 188 of about 11,456 (188)

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

Journal of Clinical Pharmacology, 2013
David Polidori, Damayanthi Devineni
exaly  

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Diabetes Care, 2015
Lawrence A Leiter, Kun Ho Yoon, Gisle Langslet   +2 more
exaly  

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

Diabetologia, 2015
David Polidori, Lawrence Blonde, John Wilding   +2 more
exaly  

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2016
Bruce Neal, Chantal Mathieu, Dick de Zeeuw   +2 more
exaly  

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Diabetes and Metabolism, 2016
Lawrence A Leiter, David Polidori, L A Leiter   +2 more
exaly  

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

Clinical Pharmacology in Drug Development, 2015
Paul Rothenberg, Hans Stieltjes, Shean-Sheng Wang   +2 more
exaly  

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

Circulation, 2019
Bruce Neal, Vlado Perkovic
exaly  

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Diabetes, Obesity and Metabolism, 2011
exaly